Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials.
Mateos MV et al. Ann Hematol. 2016 Oct 14. [Epub ahead of print].
Therapeutic experience of vincristine/cyclophosphamide/melphalan or mitoxantrone/prednisone combination therapy plus thalidomide as first-line induction therapy for newly diagnosed multiple myeloma in a single institution of China.
Wang X et al. Asia Pac J Clin Oncol. 2016 Oct 14. doi: 10.1111/ajco.12609. [Epub ahead of print].
Autologous stem cell transplantation in elderly patients with multiple myeloma: evaluation of its safety and efficacy.
Stettler J et al. Leuk Lymphoma. 2016 Oct 13:1-8. [Epub ahead of print].
Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiency.
Ogunniyi A et al. Leuk Lymphoma. 2016 Oct 13:1-7. [Epub ahead of print].
Peripheral blood stem cell mobilization in multiple myeloma comparison of two consecutive regimens in a limited resources country.
Ben Abdejlil N et al. Bone Marrow Transplant. 2016 Oct 24. doi: 10.1038/bmt.2016.246. [Epub ahead of print].
Performance assessment and benchmarking of autologous peripheral blood stem cell collection with two different apheresis devices.
Wuchter P et al. Transfus Med. 2016 Oct 11. doi: 10.1111/tme.12367. [Epub ahead of print].
Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma.
Mian I et al. Cancer. 2016 Sep 28. doi: 10.1002/cncr.30366. [Epub ahead of print].
A phase II trial of small-dose bortezomib, lenalidomide and dexamethasone (sVRD) as consolidation/maintenance therapy in patients with multiple myeloma.
Ibata S et al. Cancer Chemother Pharmacol. 2016 Oct 13. [Epub ahead of print].
Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial.
San-Miguel JF et al. Lancet Haematol. 2016 Oct 14. pii: S2352-3026(16)30147-8. doi: 10.1016/S2352-3026(16)30147-8. [Epub ahead of print].
Panobinostat plus bortezomib and dexamethasone for relapsed myeloma.
Pratt G. Lancet Haematol. 2016 Oct 14. pii: S2352-3026(16)30133-8. doi: 10.1016/S2352-3026(16)30133-8. [Epub ahead of print].
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Dimopoulos MA et al. N Engl J Med. 2016 Oct 6;375(14):1319-1331
The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma.
Hashimoto S et al. Intern Med. 2016;55(20):3025-3028. Epub 2016 Oct 15.